Continuum (Minneapolis, Minn.) · 2025
Progressive Supranuclear Palsy and Corticobasal Syndrome.
СтатьяКлинический случайОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McFarland Nikolaus R
Аннотация
OBJECTIVE: This article describes the approach to diagnosis and management of patients with progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).
LATEST DEVELOPMENTS: The clinical criteria for both PSP and CBS have expanded to include the broad phenotypic spectrum of these disorders. There is significant overlap among features of PSP and CBS, both clinically and neuropathologically, and early recognition of these disorders remains challenging. Use of novel clinical criteria increases the sensitivity and accuracy of clinician diagnosis. Advances in brain imaging techniques, such as MRI and positron emission tomography (PET), as well as fluid biomarkers, may help in diagnosis. For CBS, there is increasing recognition of varied neuropathology and differences in tau filaments, which may differentiate the disorder from PSP and other tauopathies.
ESSENTIAL POINTS: Careful attention to historical presentation, clinical features, and evolving diagnostic criteria and brain imaging techniques will help the clinician recognize the various PSP and CBS phenotypes. Early recognition is critical to provide appropriate treatment and supportive care, which ideally should involve a multidisciplinary team of allied health professionals, inclusive of the patient and the caregiver.
LATEST DEVELOPMENTS: The clinical criteria for both PSP and CBS have expanded to include the broad phenotypic spectrum of these disorders. There is significant overlap among features of PSP and CBS, both clinically and neuropathologically, and early recognition of these disorders remains challenging. Use of novel clinical criteria increases the sensitivity and accuracy of clinician diagnosis. Advances in brain imaging techniques, such as MRI and positron emission tomography (PET), as well as fluid biomarkers, may help in diagnosis. For CBS, there is increasing recognition of varied neuropathology and differences in tau filaments, which may differentiate the disorder from PSP and other tauopathies.
ESSENTIAL POINTS: Careful attention to historical presentation, clinical features, and evolving diagnostic criteria and brain imaging techniques will help the clinician recognize the various PSP and CBS phenotypes. Early recognition is critical to provide appropriate treatment and supportive care, which ideally should involve a multidisciplinary team of allied health professionals, inclusive of the patient and the caregiver.